Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00124293 · ClinicalTrials.gov registry record

Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury

A clinical trial of Trauma and Acquired Bleeding Disorder, sponsored by Novo Nordisk A/S.

Completed
Registry status
63
Enrollment target
2
Study locations

NCT00124293 is a study of Trauma and Acquired Bleeding Disorder that has completed, run by Novo Nordisk A/S. The registered enrollment target is 63 participants, below the 306-participant average among 56 other Trauma trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00124293, a study of Trauma and Acquired Bleeding Disorder, has completed, sponsored by Novo Nordisk A/S.

COMPLETED
Registry status
63 participants
Enrollment target
2
Study locations

Study Summary

This study is conducted in North America. The purpose of this study is to evaluate the occurrence and severity of bleeding in brain injury and to identify important safety issues following traumatic brain injury.

Interventions

  • DRUG activated recombinant human factor VII

Study Locations (2)

New Jersey

  • Novo Nordisk Investigational Site - Plainsboro

Other

  • Novo Nordisk Investigational Site - Mississauga

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2004-10-06
Est. Completion 2005-11-23

Sponsor

Novo Nordisk A/S

431 total trials

What the Registry Record Tells You About NCT00124293

The ClinicalTrials.gov registry entry for NCT00124293 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 306-participant average among 56 other Trauma trials with a reported enrollment target (79% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Trauma appearing as the primary indexed condition, and to 1 intervention - of which activated recombinant human factor VII is the first listed.

NCT00124293 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, Other.

Frequently Asked Questions

What is clinical trial NCT00124293 about?

NCT00124293 is a clinical study titled "Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury". This study is conducted in North America. The purpose of this study is to evaluate the occurrence and severity of bleeding in brain injury and to identify important safety issues following traumatic brain injury.

What is the current status of trial NCT00124293?

This trial is currently completed. The enrollment target is 63 participants. The study started on 2004-10-06. Estimated completion is 2005-11-23.

What conditions does trial NCT00124293 study?

This clinical trial studies the following conditions: Trauma, Acquired Bleeding Disorder.

What interventions are being tested in trial NCT00124293?

The interventions under investigation include: activated recombinant human factor VII (DRUG).

Who is sponsoring clinical trial NCT00124293?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00124293 being conducted?

This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Trauma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.